HRP20240896T1 - Derivati sulfoniluree i njihova upotreba - Google Patents
Derivati sulfoniluree i njihova upotreba Download PDFInfo
- Publication number
- HRP20240896T1 HRP20240896T1 HRP20240896TT HRP20240896T HRP20240896T1 HR P20240896 T1 HRP20240896 T1 HR P20240896T1 HR P20240896T T HRP20240896T T HR P20240896TT HR P20240896 T HRP20240896 T HR P20240896T HR P20240896 T1 HRP20240896 T1 HR P20240896T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- image
- cycloalkyl
- disease
- optionally substituted
- Prior art date
Links
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 4
- 108010034143 Inflammasomes Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 2
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 201000003377 familial cold autoinflammatory syndrome 1 Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 201000003274 CINCA syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 208000007153 proteostasis deficiencies Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860663P | 2019-06-12 | 2019-06-12 | |
| EP20733706.4A EP3983387B1 (en) | 2019-06-12 | 2020-06-11 | Sulfonylurea derivatives and uses thereof |
| PCT/EP2020/066191 WO2020249667A1 (en) | 2019-06-12 | 2020-06-11 | Sulfonylurea derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240896T1 true HRP20240896T1 (hr) | 2024-10-11 |
Family
ID=71108563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240896TT HRP20240896T1 (hr) | 2019-06-12 | 2020-06-11 | Derivati sulfoniluree i njihova upotreba |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12054461B2 (https=) |
| EP (1) | EP3983387B1 (https=) |
| JP (1) | JP7682813B2 (https=) |
| CN (1) | CN114641466B (https=) |
| DK (1) | DK3983387T3 (https=) |
| ES (1) | ES2983661T3 (https=) |
| FI (1) | FI3983387T3 (https=) |
| HR (1) | HRP20240896T1 (https=) |
| HU (1) | HUE067378T2 (https=) |
| LT (1) | LT3983387T (https=) |
| PL (1) | PL3983387T3 (https=) |
| PT (1) | PT3983387T (https=) |
| RS (1) | RS65711B1 (https=) |
| SI (1) | SI3983387T1 (https=) |
| SM (1) | SMT202400291T1 (https=) |
| WO (1) | WO2020249667A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| PL3983387T3 (pl) | 2019-06-12 | 2024-08-19 | NodThera Limited | Pochodne sulfonylomocznika i ich zastosowania |
| KR102802013B1 (ko) * | 2021-02-03 | 2025-05-07 | 환인제약 주식회사 | 알츠하이머병 치료를 위한 nlrp3 인플라마좀 소분자 억제제 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2110689A (en) | 1981-12-03 | 1983-06-22 | Sandoz Ltd | Herbicidal heterocyclic aminosulfonyl ureas and isoureas |
| CH649081A5 (de) | 1982-01-12 | 1985-04-30 | Ciba Geigy Ag | Triaza-verbindungen. |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS60214785A (ja) * | 1984-03-27 | 1985-10-28 | Nissan Chem Ind Ltd | ピラゾ−ルスルホニルウレア誘導体、および植物生長調節剤または除草剤 |
| US5214206A (en) | 1990-11-07 | 1993-05-25 | Warner-Lambert Company | Aminosulfonyl urea acat inhibitors |
| CA2115990A1 (en) | 1991-08-19 | 1993-03-04 | George Albert Boswell | Angiotensin ii receptor blocking imidazolinone derivatives |
| WO1993004045A1 (en) | 1991-08-19 | 1993-03-04 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazolinone derivatives |
| NZ247440A (en) | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| DE4217719A1 (de) * | 1992-05-29 | 1993-12-02 | Bayer Ag | Zweifach heterocyclisch substituierte Sulfonylamino(thio)carbonylverbindungen |
| DE4302701A1 (de) | 1993-02-01 | 1994-08-04 | Bayer Ag | Arylaminosulfonylharnstoffe |
| DE4302702A1 (de) | 1993-02-01 | 1994-08-04 | Bayer Ag | Arylaminosulfonylharnstoffe |
| JP3355237B2 (ja) | 1993-10-15 | 2002-12-09 | 呉羽化学工業株式会社 | Ｎ−（置換アミノ）ピロール誘導体、その製造方法及び除草剤 |
| JPH0827147A (ja) * | 1994-07-20 | 1996-01-30 | Kureha Chem Ind Co Ltd | Ｎ−（置換アミノ）イミド誘導体、その製造方法及び除草剤 |
| JPH09132574A (ja) | 1995-11-09 | 1997-05-20 | Nissan Chem Ind Ltd | フルオロプロピルチアゾリン誘導体の製造法 |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US6028201A (en) | 1996-01-30 | 2000-02-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
| JPH1029990A (ja) | 1996-07-12 | 1998-02-03 | Kureha Chem Ind Co Ltd | １−（置換アミノ）イミダゾール誘導体、その製造方法及び除草剤 |
| DE19651037A1 (de) | 1996-12-09 | 1998-06-10 | Bayer Ag | Substituierte Thienyl(amino)sulfonyl(thio)harnstoffe |
| PT1270565E (pt) | 1997-01-29 | 2004-09-30 | Pfizer | Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia |
| IT1290062B1 (it) | 1997-03-13 | 1998-10-19 | Isagro Ricerca Srl | Amminosolfoniluree ad attivita' erbicida |
| GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
| DE19937118A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Substituierte Thienyl(amino)sulfonylharnstoffe |
| JP4112127B2 (ja) | 1999-08-31 | 2008-07-02 | 株式会社リコー | 感熱記録材料 |
| AU7447500A (en) | 1999-09-30 | 2001-04-30 | Mitsubishi Chemical Corporation | Acylsulfonamide derivatives |
| US6593356B2 (en) | 1999-10-20 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| EP1281399A3 (en) | 2001-08-01 | 2004-02-11 | Warner-Lambert Company | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
| WO2003029226A1 (en) | 2001-09-26 | 2003-04-10 | Basf Aktiengesellschaft | Heterocyclyl substituted phenoxyalkyl-, phenylthioalkyl-, phenylaminoalkyl- and phenylalkyl-sulfamoylcarboxamides |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
| AU2005325676A1 (en) | 2004-12-23 | 2006-08-03 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2013119040A1 (en) | 2012-02-07 | 2013-08-15 | Kainos Medicine, Inc. | Compounds as inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| CN103288750A (zh) | 2013-03-04 | 2013-09-11 | 盐城工学院 | 新型氨基磺酰脲类化合物 |
| US9410217B2 (en) | 2014-02-18 | 2016-08-09 | Renmatix, Inc. | Method of reducing a fermentation and/or enzyme inhibitor in a saccharide-containing composition |
| SI3259253T1 (sl) | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| EP3272739A1 (en) * | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| ES2988798T3 (es) | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| JP2020531435A (ja) * | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| US20210122739A1 (en) | 2017-08-15 | 2021-04-29 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3668601A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) * | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201902327D0 (en) * | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| KR20210053910A (ko) * | 2018-08-15 | 2021-05-12 | 인플라좀 리미티드 | 신규한 설폰아마이드유레아 화합물 |
| PL3983387T3 (pl) | 2019-06-12 | 2024-08-19 | NodThera Limited | Pochodne sulfonylomocznika i ich zastosowania |
| EP3983388A1 (en) | 2019-06-12 | 2022-04-20 | Nodthera Limited | Sulfonamide derivatives and uses thereof |
| JP7661248B2 (ja) | 2019-06-12 | 2025-04-14 | ノッドセラ リミテッド | スルホニル尿素誘導体及びその使用 |
| IL301055A (en) | 2020-09-04 | 2023-05-01 | Nodthera Ltd | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof |
-
2020
- 2020-06-11 PL PL20733706.4T patent/PL3983387T3/pl unknown
- 2020-06-11 CN CN202080057162.2A patent/CN114641466B/zh active Active
- 2020-06-11 ES ES20733706T patent/ES2983661T3/es active Active
- 2020-06-11 SM SM20240291T patent/SMT202400291T1/it unknown
- 2020-06-11 PT PT207337064T patent/PT3983387T/pt unknown
- 2020-06-11 EP EP20733706.4A patent/EP3983387B1/en active Active
- 2020-06-11 WO PCT/EP2020/066191 patent/WO2020249667A1/en not_active Ceased
- 2020-06-11 LT LTEPPCT/EP2020/066191T patent/LT3983387T/lt unknown
- 2020-06-11 RS RS20240765A patent/RS65711B1/sr unknown
- 2020-06-11 DK DK20733706.4T patent/DK3983387T3/da active
- 2020-06-11 US US17/618,184 patent/US12054461B2/en active Active
- 2020-06-11 HU HUE20733706A patent/HUE067378T2/hu unknown
- 2020-06-11 JP JP2021573382A patent/JP7682813B2/ja active Active
- 2020-06-11 FI FIEP20733706.4T patent/FI3983387T3/fi active
- 2020-06-11 SI SI202030459T patent/SI3983387T1/sl unknown
- 2020-06-11 HR HRP20240896TT patent/HRP20240896T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3983387T3 (da) | 2024-07-15 |
| US12054461B2 (en) | 2024-08-06 |
| PT3983387T (pt) | 2024-07-10 |
| US20220227715A1 (en) | 2022-07-21 |
| SI3983387T1 (sl) | 2024-09-30 |
| FI3983387T3 (fi) | 2024-07-09 |
| RS65711B1 (sr) | 2024-08-30 |
| EP3983387B1 (en) | 2024-04-24 |
| PL3983387T3 (pl) | 2024-08-19 |
| SMT202400291T1 (it) | 2024-09-16 |
| CN114641466B (zh) | 2025-09-30 |
| ES2983661T3 (es) | 2024-10-24 |
| EP3983387A1 (en) | 2022-04-20 |
| JP7682813B2 (ja) | 2025-05-26 |
| HUE067378T2 (hu) | 2024-10-28 |
| JP2022535956A (ja) | 2022-08-10 |
| CN114641466A (zh) | 2022-06-17 |
| LT3983387T (lt) | 2024-07-25 |
| WO2020249667A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250964T1 (hr) | Derivati sulfonil ureje kao modulatori nlrp3 inflamasoma | |
| HRP20211225T1 (hr) | Sulfoniluree i srodni spojevi i njihova uporaba | |
| HRP20240896T1 (hr) | Derivati sulfoniluree i njihova upotreba | |
| HRP20201263T1 (hr) | Natrijeva sol od n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida | |
| HRP20231690T1 (hr) | Selektivni inhibitori nlrp3 inflamasoma | |
| HRP20240521T1 (hr) | Spojevi i pripravci za liječenje stanja povezanih s aktivnošću nlrp | |
| BR112021016751B8 (pt) | Compostos, composições farmacêuticas e usos dos compostos | |
| HRP20251344T1 (hr) | SPOJEVI I PRIPRAVCI ZA LIJEČENJE STANJA POVEZANIH S AKTIVNOŠĆU NLRP-a | |
| HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
| HRP20211583T1 (hr) | Tienopiridini i benzotiofeni korisni kao irak4 inhibitori | |
| JP2018510207A5 (https=) | ||
| IL271716B1 (en) | Sulfonamide carboxamide compounds as nlrp3 inhibitors, pharmaceutical compositions and uses thereof | |
| JP2021511374A5 (https=) | ||
| HRP20210472T1 (hr) | Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4 | |
| HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20230052T1 (hr) | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| IN2014MN01839A (https=) | ||
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| JP2020525513A (ja) | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 | |
| HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
| JP2023532298A (ja) | 化合物、組成物及び方法 | |
| CA3068395A1 (en) | 2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
| MX2025010782A (es) | Compuestos de piridazina, su preparacion y sus usos terapeuticos | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti |